# An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

> **NCT02207816** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3084 (actual)

## Conditions studied

- Malaria

## Interventions

- **PROCEDURE:** Blood sampling
- **BIOLOGICAL:** Malaria Vaccine 257049 (MALARIA-055 PRI)
- **BIOLOGICAL:** Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- **BIOLOGICAL:** Cell-culture rabies vaccine (MALARIA-055 PRI)
- **BIOLOGICAL:** TritanrixHepB/Hib (MALARIA-055 PRI)
- **BIOLOGICAL:** Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)

## Key facts

- **NCT ID:** NCT02207816
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-18
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-01-31
- **Target enrollment:** 3084 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207816, "An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02207816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*